Arcellx is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Existing cell therapy solutions tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these limitations by engineering a new class of D-Domain powered autologous and allogeneic Chimeric Antigen Receptor T cells (CAR-Ts), including classical single infusion CAR-Ts called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. We are preparing to initiate our iMMagine Phase 2 pivotal trial of CART-ddBCMA, our lead ddCAR product candidate, in patients with relapsed or refractory multiple myeloma in late 2022, and if successful, intend to submit a Biologics License Application to the U.S. Food and Drug Administration. We plan to initiate a Phase 1 clinical trial of ACLX-001, the first product candidate developed under our ARC-SparX platform, for the treatment of r/r MM in the first half of 2022.